Alpha memo: resveratrol exercise training cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Explicitly label Receipt 1 as a murine mechanistic study (intestinal inflammation/ferroptosis, Nrf2/FTH1/GPX4 pathway) and Receipt 2 as a human RCT (cardiovascular endpoints, aged men, 250 mg/day trans-resveratrol) so the cross-context contrast is transparent.
2. Tone down the 'reversal' framing to 'context- and endpoint-dependent divergence' to avoid implying direct contradiction across heterogeneous endpoints/species.
3. Add a brief named limitations paragraph covering species difference, tissue specificity (gut vs. vasculature), dose comparability, and training protocol differences (swimming mice vs. HIIT humans).
4. State the bounded signal as: resveratrol's net effect when combined with exercise training is contingent on species, tissue, endpoint, and dose, rather than implying a clean mechanistic-to-clinical reversal.

Major issues

• The memo presents a 'mechanism-to-human-failure' contrast but does not explicitly state that Receipt 1 is a murine mechanism study (intestinal inflammation/ferroptosis via Nrf2/FTH1/GPX4) while Receipt 2 is a human cardiovascular RCT (vascular function, aged men). The cross-context bridge is implied but never made explicit, so the bounded signal is partially hidden.
• Receipt 1 and Receipt 2 examine different endpoints (intestinal inflammation/ferroptosis in mice vs. cardiovascular health in aged men), different species, and different outcome domains. Treating the pair as a single 'reversal' is overclaim without explicit acknowledgment that the endpoints and tissues differ.

Minor issues

• The 'Why this is surprising' section uses idiosyncratic framing ('mechanism_to_human_failure geometry') that is not defined or sourced; consider plain-language summary.
• No explicit limitations section beyond the falsifiers list — the memo would benefit from a short named limitations block clarifying context-dependence, dose differences (15 mg/kg/day mice vs. 250 mg/day humans), and tissue-specificity.
• DOI suffix format for the first receipt (10.55730/1300-0144.5604) is unusual; verify it resolves correctly.

Reviewer note

The memo selects a coherent receipt pair (resveratrol + exercise training) and identifies a real divergence between a 2023 murine mechanistic study (intestinal ferroptosis/inflammation, Nrf2/FTH1/GPX4) and a 2013 human RCT (cardiovascular outcomes in aged men). The source bundle directly supports the cited findings. However, the memo does not explicitly label the species, tissue, and endpoint differences that make the 'reversal' framing misleading, and uses geometric jargon ('mechanism_to_human_failure geometry') without definition. The abstract's 'fail, reverse, or split by context' language is restrained but the body does not operationalize the contexts. With bounded edits making the species/tissue/endpoint contrast explicit and softening the reversal framing to context-dependent divergence, this becomes an acceptable alpha-memo. Recommendation: revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis